tbuckley/cabot-search huggingface dataset:
SAT0497 The Influence of Age, Gender, Tobacco and Manual Tasks in the Presence of Power Doppler Signal in Subjects with Non Inflammatory Arthritides
Authors: M. J. Audisio, A. M. Bertoli, G. E. Py, I. Strusberg
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Power Doppler (PD) ultrasound is a sensitive and reliable method for the assessment of inflammatory activity in rheumatoid arthritis (RA). Many variables, however, were described to modulate the presence of PD signal, and, therefore, its sensitivity and specificity, including, but not limited to, the equipment, the operator and room temperature. <h3>Objectives</h3> To assess the presence of PD signal at the wrist and metacarpophalangeal (MCP) joints in subjects with non-inflammatory arthritides according to gender, age, work type (manual task versus non-manual task). and smoking status. <h3>Methods</h3> The wrist and MCP´s of the dominant hand of 182 subjects (75 with diagnosis osteoarthritis of the hand as per the ACR criteria and 107 with no identifiable joint disease) were examined for the presence PD signal. The influence of age, gender, tobacco use and manual tasks on the presence of PD signal was examined using the Chi square and student´s T test. <h3>Results</h3> Subjects were predominantly females (79%) and they had a mean (SD) age of 47.9 (15.5) years. Twenty nine (16%) used tobacco and 73 (40%) performed manual tasks. Nineteen (10%) subjects had PD signal at any of the examined joints, 16 (9%) at the wrist and 3 (1.6%) at the MCP´s. The Table below depicts the influence of age, gender, tobacco use and manual tasks on the presence of PD signal. <h3>Conclusions</h3> In this study, neither gender nor the type of work (manual versus non manual) or smoking seems to influence the chances to find PD signal in the joints. On the contrary, age was significantly associated with the presence of PD signal, with older patients being more able to display positive findings. The latter should be considered as a practical consideration when performing ultrasound PD examination. <h3>Disclosure of Interest</h3> None Declared
Carcinogenicity and Pulmonary Pathology Associated With a Single 2-Hour Inhalation Exposure of Laboratory Rodents to Methyl Isocyanate
Authors: J. R. BUCHER, L. C. URAIH, P. K. HILDEBRANDT, R. M. SAUER, J. C. SEELY
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Carcinogenicity and Pulmonary Pathology Associated With a Single 2-Hour Inhalation Exposure of Laboratory Rodents to Methyl Isocyanate Get access JOHN R. BUCHER, JOHN R. BUCHER National Toxicology Program, National Institute of Environmental Health SciencesP.O. Box 12233 Research Triangle Park, NC 27709 Search for other works by this author on: Oxford Academic PubMed Google Scholar LINDA C. URAIH, LINDA C. URAIH National Toxicology Program, National Institute of Environmental Health SciencesP.O. Box 12233 Research Triangle Park, NC 27709 Search for other works by this author on: Oxford Academic PubMed Google Scholar PAUL K. HILDEBRANDT, PAUL K. HILDEBRANDT PATHCO, Inc.Gaithersburg, MD 21754 Search for other works by this author on: Oxford Academic PubMed Google Scholar ROBERT M. SAUER, ROBERT M. SAUER PATHCO, Inc.Gaithersburg, MD 21754 Search for other works by this author on: Oxford Academic PubMed Google Scholar JOHN C. SEELY JOHN C. SEELY PATHCO, Inc.Gaithersburg, MD 21754 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 20, 18 October 1989, Pages 1586–1587, https://doi.org/10.1093/jnci/81.20.1586 Published: 18 October 1989
Incidental Detection of Gastrointestinal Stromal Tumor by Tc-99m MDP Bone Scan
Authors: Timothy M Shepherd, Ibrahim A Idakoji, Miguel H Pampaloni
Journal: Clinical Nuclear Medicine (2012)

This case demonstrates extraosseous 99m-technetium methylene diphosphonate (Tc-99m MDP) accumulation from a gastrointestinal stromal tumor. A 75-year-old woman underwent a temporal bone CT for conductive hearing loss that showed sclerosis in the right occipital condyle. Follow-up Tc-99m MDP bone scan for osseous metastases instead showed a mass-like extraosseous accumulation of Tc-99m MDP in the anterior left upper quadrant. Differential diagnoses included gastric cancer, lymphoma, metastatic melanoma, systemic hypercalcemia, or heterotopic mesenteric ossification. Contrast CT showed a well-circumscribed mass arising from the stomach, and subsequent pathology confirmed gastrointestinal stromal tumor. These tumors rarely can contain osteoclast-like giant cells and should be considered for extraosseous Tc-99m MDP accumulation.
Cerebral Microsporidiosis Due to<i>Encephalitozoon cuniculi</i>in a Patient with Human Immunodeficiency Virus Infection
Authors: Rainer Weber, Peter Deplazes, Markus Flepp, Alexander Mathis, Reinhard Baumann, Bärbel Sauer, Herbert Kuster, Ruedi Lüthy
Journal: New England Journal of Medicine (1997)

Microsporidia are obligate, intracellular, spore-forming protozoa that are parasitic in every major animal group.1 Cerebral microsporidial infection was first described in 1922 in rabbits with granulomatous encephalitis,2 and the organism was named Encephalitozoon cuniculi. 3 In 1959 and 1984, two cases of infection in children with seizure disorders were attributed to E. cuniculi. 4,5 The diagnosis was based on light-microscopical detection of microsporidial spores in cerebrospinal fluid and urine samples, but the identification of the species remained inconclusive, because immunologic and molecular techniques to distinguish among encephalitozoon-like microsporidia were not available at that time. In recent years, three distinct encephalitozoon species . . .
Abstract 4135: Plasma miRNAs as potential predictive/prognostic biomarker for ovarian cancer
Authors: Kexin Chen
Journal: Cancer Research (2012)

Abstract Background: Ovarian cancer is the fifth leading cause of cancer death in women worldwide. While the survival rates of women with early stage ovarian cancer are high, most cases are diagnosed late. Due to asymptomatic development and few screening options, almost 70% of women present at late stages of carcinogenesis. Sensitive, non-invasive biomarkers that can facilitate disease detection, staging and prediction of therapeutic outcome are highly desirable to improve survival rate and help to determine optimized treatment for ovarian cancer. The small non-coding RNAs, microRNAs (miRNAs), have recently been identified as critical regulators for various diseases including cancer and may represent a novel class of cancer biomarkers. The purpose of this study was to identify and validate circulating microRNAs in human plasma for use as such biomarkers in ovarian cancer. Methods/ Principle findings: We scan the circulating plasma miRNAs by Taqman Low Density Array, then identify and validated 30 markers in plasma samples among 70 cases and 70 controls by real-time PCR assay. Promising associations were evaluated in a second stage, comprising 150 cases and 150 controls. We found that compared with normal, there are 9 miRNAs (miR-205, miR-200a, miR-184, miR-34a*, miR-141, miR-483-5p, miR-193b*, let-7e*, miR-363*) expressed higher in ovarian cancer group, while the miR-98 and let-7f have the lower levels in ovarian cancer. Compared with early stage cases (stage I), there is only miR-483-5p expressed higher in advanced stages (stage II-IV). Receiver operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of candidate plasma microRNA markers. We observed that combination of these identified miRNAs and CA-125, a widely used marker for ovarian cancer, further improved the accuracy of detection. Furthermore, our analysis showed that high levels of plasma miR-483-5p or low levels of let-7f predicted poor prognosis of ovarian cancer patients, consistent with the expression of miRNAs in ovarian cancer tissues. Conclusions/Significance: We propose that plasma miRNAs (miR-205, miR-200a, miR-184, miR-34a*, miR-141, miR-483-5p, miR-193b*, let-7e*, miR-363*) are potential biomarkers that complements CA-125 in detecting ovarian cancer; miR-483-5p and let-7f may predict the prognosis of ovarian cancer. It may provide new avenues for the detection, diagnosis, and therapy of this deadly disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4135. doi:1538-7445.AM2012-4135
Abstract 1781: LGI147, a novel small-molecule inhibitor of the mitotic kinesin Eg5, shows anticancer effects in human hepatocellular carcinoma
Authors: Zhong-Zhe Lin, Chi-Ying F. Huang, Hung-Wei Pan, Nai-Yun Sun, Li-Pin Hsiao, Hey-Chi Hsu, Ann-Lii Cheng
Journal: Cancer Research (2012)

Abstract Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, for which novel therapies are urgently needed. Recently, the inhibitors of mitotic kinesin Eg5 emerge as potential anticancer therapeutics. The aim of this study was to investigate the anticancer activity of a potent Eg5 inhibitor, LGI147, as targeted therapy of HCC. Method: Antiproliferative effect of LGI147 (kindly provided by Novartis), a highly selective inhibitor of mitotic kinesin Eg5, was tested in three liver cancer cell lines (Hep3B, HepG2, PLC/PRF/5). Cell viability was measured by trypan blue exclusion assay. Mitotic perturbation was visualized by immunofluorescence staining and confocal microscopy. Cell cycle profiles were assessed by flow cytometry. Apoptosis was estimated by analysis of sub-G1 fraction, Annexin V expression and immunoblotting of apoptotic proteins. Results: LGI147 induced a dose-dependent growth inhibition with IC50s ranging from 43.47 pM to 53.59 pM in the tested HCC cell lines. LGI147 treatment for 24 hours led to inhibition of Eg5 activity and induction of abnormal mitosis in a dose-dependent manner. Polypolar spindle defects in mitosis, disturbed cell cycle progression, and induction of apoptosis were observed in the HCC cells treated with LGI147. Conclusions: These findings show that LGI147 has potent anticancer effects in human HCC. Inhibitors of mitotic kinesin Eg5 may deserve further exploration as molecular targeted agents against HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1781. doi:1538-7445.AM2012-1781
Gene-Marking Studies in Bone Marrow May Yield Treatments
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Gene-Marking Studies in Bone Marrow May Yield Treatments Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 22, 17 November 1993, Pages 1799–1800, https://doi.org/10.1093/jnci/85.22.1799 Published: 17 November 1993
Abstract 2355: Role of secreted frizzled-related protein 3 (sFRP3) in human renal cell carcinoma
Authors: Hiroshi Hirata, Yuji Hinoda, Koji Ueno, Shahana Majid, Sharanjot Saini, Rajvir Dahiya
Journal: Cancer Research (2010)

Abstract Wnt/beta-catenin signaling is involved in renal cancer. Among Wnt antagonist families, sFRP3 is generally thought to be an inhibitor of Wnt signaling in several cancers. Here we reported the functional significance of sFRP3 in renal cell carcinoma. We performed immunohistochemistry on kidney tissue microarray and confirmed the expression level of sFRP3 in normal kidney and renal cancer cell lines (primary and metastatic). We transfected sFRP3 to the primary renal cancer cell lines and performed several functional analysis (MTS, colony formation, apoptosis, cell cycle, invasion, angiogenesis, and in vivo study). We also knocked down sFRP3 mRNA in metastatic cell lines using siRNA technique and performed several functional analysis. We found the level of sFRP3 protein was high in normal kidney, low in primary renal cancer tissues and high in metastatic renal cancer tissues. We performed dual sFRP3 mRNA expression experiments to determine the role of sFRP3 using primary and metastatic renal cancer cell lines. Functional analysis showed increased numbers of viable and invaded cells, tube formation and decreased numbers of apoptotic cells in sFRP3 transfected A498 cells. Promotion of tumor growth was also observed in nude mice injected with sFRP3 transfected A498 cells. In contrast, the number of viable cells and invasive cells was decreased in sFRP3 mRNA knocked down metastatic cells (ACHN and Hs891.T). To investigate the mechanism of sFRP3 function, we performed microarray analysis to see which genes were up or down regulated by sFRP3 expression. Among these genes, MMP-3 and ANGPT1 were significantly up-regulated in sFRP3 transfected cells. This is the first report to show that sFRP3 expression promotes cell growth, invasion, and inhibition of apoptosis in renal cancer cells. Furthermore, our results suggest that sFRP3 may play a role in invasion and angiogenesis by enhancing MMP-3 and ANGPT1 expression. The changes in sFRP3 expression levels in normal, primary cancer, and metastatic renal cancer tissues suggest that sFRP3 may play dual roles as a tumor suppressor gene and an oncogene during renal cancer progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2355.
TCT-403 Peripheral Endothelial Function and Sympathetic Influence on Dermal Microcirculation Correlate with Long-Term Blood Pressure Response in Renal Denervation Patients
Authors: Alexander Jabs, Meike Fluhr, Katharina Beck, Selina Muxel, Zsofia Bardonicsek, Thomas Munzel, Tommaso Gori, Ulrich Hink
Journal: Journal of the American College of Cardiology (2014)
PTH-101 The Burden of Iron Deficiency Anaemia in a Tertiary IBD Centre Population
Authors: S Esmaily, S Hearnshaw, J Mansfield, R Speight, M Gunn
Journal: Gut (2013)

<h3>Introduction</h3> Anaemia is the most common extraintestinal manifestation of IBD, with iron deficiency being the most prevalent cause. The ECCO guidelines published in 2012 included the management of anaemia in UC. Previous studies have shown up to 1/3 of the IBD population are anaemic. Anaemia may affect quality of life in patients. There remains uncertainty in the clinical benefit in treatment of mildly anaemic and iron deficient patients. The aim of the study was to identify the burden of iron deficiency anaemia in patients with IBD in a tertiary referral centre and whether we are treating this according to the ECCO guidelines. <h3>Methods</h3> Consecutive patients with IBD reviewed in general gastroenterology and specialist IBD clinics during one month period extending from the 1st of December 2012 to the 1st of January 2013 were included. Hb, MCV, ferritin and transferrin saturations were recorded. Results were documented prospectively. Iron deficiency was diagnosed on the basis of recent ECCO guidelines. Anaemia was defined as Hb &lt; 12 g/dL in females and &lt; 13 g/dL in males Treatment with oral or parenteral iron was also noted. <h3>Results</h3> Out of 104 patients seen during this period, 21 (20.2%) patients had iron deficiency out of which 11 (10.6%) were anaemic. 3/11 (27.3%) patients with iron deficiency anaemia had a Hb of less than 10, 2/3 of which received parental iron. One received no treatment. Out of the remaining patients with milder iron deficiency anaemia (Hb &gt; 10 g/dL), 3 had no treatment, 1 had IV only, 2 had oral only and 2 had both IV and oral. In the Iron deficient non anaemic group, 6/10 had no treatment, 2/10 had oral iron and 2/10 had parental iron. <h3>Conclusion</h3> Our study showed 20.2% of IBD patients attending over a one month period had iron deficiency anaemia or iron deficiency. Treatment of iron deficiency with and without anaemia is variable and could improve with adherence to a clear protocol. The question of whether the treatment of iron deficiency without significant anaemia in IBD improves fatigue and QOL requires further research. <h3>Disclosure of Interest</h3> None Declared.
Mechanisms of Airway Remodeling
Authors: JUDITH L. BLACK, MICHAEL ROTH, JinHEE LEE, STEPHEN CARLIN, PETER R. A. JOHNSON
Journal: American Journal of Respiratory and Critical Care Medicine (2001)

Section:ChooseTop of pageAbstract <<AIRWAY SMOOTH MUSCLE AND ...AIRWAY SMOOTH MUSCLE PROL...AIRWAY SMOOTH MUSCLE AND ...AIRWAY SMOOTH MUSCLE CELL...ASTHMATIC AIRWAY SMOOTH M...CONCLUSIONS AND FUTURE RE...ReferencesCITING ARTICLES
Influence of Multigland Parathyroid Disease on 99mTc-Sestamibi SPECT/CT
Authors: Kenneth James Nichols, Gene G. Tronco, Christopher J. Palestro
Journal: Clinical Nuclear Medicine (2016)

99mcTc-sestamibi (MIBI) imaging is performed for preoperative parathyroid lesion localization in patients with primary hyperparathyroidism. Decreased sensitivity in multigland disease (MGD) compared with single-gland disease (SGD) is well recognized for planar and SPECT imaging, but few data are available on MIBI SPECT/CT in MGD.We retrospectively analyzed 246 patients with primary hyperparathyroidism who underwent preoperative MIBI SPECT/CT. Surgical and pathology reports were used to confirm numbers, weights, and locations of excised glands. Two experienced physicians independently read MIBI SPECT/CTs, grading lesion certainty on a 5-point scale ("definitely normal" to "definitely abnormal").Three hundred one parathyroid lesions were excised at surgery. Thirty-nine patients (16%) had MGD, and 207 patients (84%) had SGD; 26 patients had 2 lesions, 10 had 3 lesions, and 3 had 4 lesions. Lesion weights were significantly lower in MGD than in SGD (390 ± 604 vs 866 ± 933 mg, P < 0.0001) and decreased with increasing numbers of lesions (P < 0.0001). MIBI SPECT/CT was less sensitive for MGD than SGD (66% vs 98%, P < 0.0001). Sensitivity was lower for 66 MGD lesions matched to 66 SGD lesions (64% vs 98%, P < 0.0001) and decreased with increasing lesion numbers (ρ = -0.45, P < 0.0001), despite similar weights (526 ± 678 vs 525 ± 686 mg, P = 0.99) and similar locations (P = 0.47). Specificity was similar for MGD (95%) and SGD (90%).99mcTc-MIBI SPECT/CT sensitivity is significantly lower in MGD than in SGD. This does not appear to be related to lesion weight or location.
PTU-097 Medical resource utilisation and costs in patients with ulcerative colitis in the UK: a chart review analysis: Abstract PTU-097 Table 1
Authors: K Bodger, L Yen, A Szende, G Sharma, J McDermott, J Y Chen, P Hodgkins
Journal: Gut (2012)

<h3>Introduction</h3> Limited evidence is available on the economic burden of ulcerative colitis (UC) in the UK, particularly in relation to the impact of relapse frequency on direct medical costs. The objective of this study was to quantify annual disease-related and all-cause (total) medical resource utilisation (MRU) and associated direct medical costs. <h3>Methods</h3> A retrospective chart review of patients with mild-to-moderate UC diagnosed at least 1 year prior to the study was performed. From 33 general practitioner (GP) and 34 gastroenterologist sites in UK, charts of the last three UC patients meeting the study9s inclusion criteria were reviewed. 2009–2010 National Health Service reference costs were assigned to the recorded medical resources. Descriptive statistics were calculated for disease-related and all-cause MRU and costs by number of relapses. Logistic regression was used to estimate MRU and costs while accounting for relapse status, patient demographics, site type, and treatment setting. <h3>Results</h3> Study population: N=201 patients; mean age: 39.9 years; 44% female; mean disease duration: 7.4 years. UC-related costs of each MRU category increased with the number of relapses. Comparing those without relapse to patients with &gt;2 relapses, mean annual UC-related costs were £14 vs £2556 for hospitalisations; £239 vs £2221 for visits; £21 vs £1303 for procedures; £16 vs £188 for diagnostics. Age, gender, and site of data reporting (GP vs gastroenterologist) were not related to MRU or costs. <h3>Conclusion</h3> Patients with mild-to-moderate UC have considerable care costs which increase significantly with the number of relapses. These findings support the importance of maintenance therapies in UC that aim to reduce relapse. Quantifying the relationship between relapse rate and costs will inform future health economic studies. <h3>Competing interests</h3> K Bodger: Consultant for: Dr Bodger received funding from Covance Market Access Services, L Yen: Shareholder with: MsYen is a Shire Development LLC, shareholder, Employee of: MsYen is a Shire Development LLC, employee, A Szende: Grant/Research Support from: Dr Szende is a Covance Market Access Services (CMA) employee CMA received funding from Shire, G Sharma: Grant/Research Support from: Dr Sharma is a Covance Market Access Services (CMA) employee CMA received funding from Shire, J McDermott Grant/Research Support from: Mr McDermott is a Covance Market Access Services (CMA) employee CMA received funding from Shire, J Chen: Grant/Research Support from: MsChen is a Covance Market Access Services (CMA) employee CMA received funding from Shire, P Hodgkins Shareholder with: Dr Hodgkins is a Shire Development LLC, shareholder, Employee of: Dr Hodgkins is a Shire Development LLC, employee.
Effects of Different Forms of Dietary Hydrogenated Fats on Serum Lipoprotein Cholesterol Levels
Authors: Alice H. Lichtenstein, Lynne M. Ausman, Susan M. Jalbert, Ernst J. Schaefer
Journal: New England Journal of Medicine (1999)

Metabolic studies suggest that fatty acids containing at least one double bond in the trans configuration, which are found in hydrogenated fat, have a detrimental effect on serum lipoprotein cholesterol levels as compared with unsaturated fatty acids containing double bonds only in the cis configuration. We compared the effects of diets with a broad range of trans fatty acids on serum lipoprotein cholesterol levels.
Abstract 17219: Vitamin D Supplementation Improves Endothelial Function In Type 2 Diabetes - A Randomized Controlled Trial
Authors: Kristin Angel, Hanne L Gulseth, Cecilie Wium, Dan Atar, Erik F Eriksen, Kaare Birkeland
Journal: Circulation (2013)

Background: Cardiovascular disease is prevalent in type 2 diabetes, and both endothelial dysfunction and arterial stiffness may contribute in the pathogenesis. Studies indicate that low levels of vitamin D are associated with both type 2 diabetes and cardiovascular disease. Aim: To evaluate the effect of vitamin D supplementation on endothelial function and arterial stiffness in subjects with type 2 diabetes in the DIVINE study. Methods: Sixty-two subjects with type 2 diabetes and hypovitaminosis D (serum 25-hydroxy-vitamin D [25(OH)D] <50 nmol/L) were included in this randomized controlled trial (NCT 00992797). Thirty-three patients were randomized to treatment and received vitamin D (400 000 IU cholecalciferol) at baseline with dose escalation to elevate serum levels to more than 100 nmol/L after 4 weeks, whereas 29 patients received placebo. Endothelial function and arterial stiffness were measured at baseline and after six months. Endothelial function was assessed as the reactive hyperaemia index (RHI...